This study aimed at assessing the global value of AdvateTM, antihaemophilic recombinant factor for bleeding
prevention and control in Haemophilia A.
Epidemiological, clinical, organizational and social and ethical data related to available Haemophilia
treatments were considered.
Scientific literature reviews were conducted through all main electronic databases.
A cost-effectiveness analysis (CEA) from the perspective of the National Health Service (NHS) was performed
in order to calculate the incremental cost-effectiveness ratio (ICER) comparing the use of octocog alfa in
primary prophylaxis vs on-demand treatment.
In the world, patients with Haemophilia A are approximately 110,000 (about 3700 in Italy). Prophylaxis,compared to on-demand treatment, is proven to be more effective for prevention of bleedings and related
complications, but also moderately more expensive (ICER= €35,036/QALY). The introduction of totally
protein-free full length recombinant FVIII concentrates (AdvateTM), eliminated risks of blood-borne pathogens
transmission. This induced a broader adoption of prophylaxis improving efficacy of treatment and
patients’ Quality of Life (QoL).
Also, since Baxter, AdvatÈs manufacturer and distributor, offers collateral free of charge services to patients
(home delivery, home rehabilitation assistance, home nursing, telemedicine), the HTA looks at how all these
services generate savings for the healthcare authorities while increasing the level of assistance.
The evidence provided by HTA should be taken into account by decision-makers to improve the allocation
of resources and rationalize health choices.
|Titolo tradotto del contributo||[Autom. eng. transl.] AdvateTM Health Technology Assessment (octocog alfa) for the prophylaxis of bleeding in patients with Hemophilia A. Ann Ig 2013; 25 (Suppl. 1): 1-7|
|Numero di pagine||7|
|Rivista||ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITÀ|
|Stato di pubblicazione||Pubblicato - 2013|
- Health Technology Assessment
- Octocog alpha